Recently, Morel et al. reported that EZH2 depletion/inhibition upregulated IFN pathways and potentiated response to PD-1 therapy in prostate cancer [68], which may be similar for MRT and ovarian cancers. The gene discussed is EZH2; the disease is prostate carcinoma.